The View from Pharma-dur

Dr. Joan Bushwell's Chimpanzee Refuge

Category archives for The View from Pharma-dur

I am so pleased to see that Adam Kay’s masterwork has made it to the big time: YouTube. Happy holidays, bonobos! (Pharma-phunnies, some medically graphic, contained therein.)

So. The new gig.

After coping with an immediate family member’s severe illness (thankfully resolved; better living through chemistry pays off) and discovering that my talents do not lie in management within a very large company, I stepped back from my almost 20 year career in discovery research several months ago. I gleefully wallowed around the home front, decompressing…

Personalized Pharmaceuticals

Finally! A prescription medication tailor-made for me! From the makers of Damitol and Fukitol, here is…

Judah Folkman: 1933-2008

Judah Folkman, a most extraordinary scientist, died Monday at age 74. Orac (Respectful Insolence) posted a fitting tribute which I highly recommend. See also Alex’s (Daily Transcript) entry and this New York Times article. Thanks to the intricate academic vascular network between Harvard and Boston biotech, Folkman visited the company in Cambridge MA for which…

George Clooney, You, and Chantix

One of the more recent offerings in the pernicious practice of direct-to-consumer (DTC) advertising from Big Pharma is a tortoise and a hare hawking a smoking cessation med: Chantix. The drug, varenicline tartrate, has a dual action in that it acts as both a partial agonist (enhancing activity but not by too much) and antagonist…

One of my to-do tasks includes making some revisions to a standard operating procedure draft document for lab notebook policies for our division. I’m a member of an “executive lab notebook committee” or as I fondly like to call my assignment, the stinking albatross that hangs around my neck. The confluence of discovery scientists and…

When I find myself in times of trouble Ben and Jerry’s comes to me Snarfing Chunky Monkey so sweetly, so sweetly. When stressed, some folks barely eat and consequently lose weight. Others, including myself, reach for high-fat-high-sugar (HFS) foods in an attempt to ameliorate the angst. Although the connection between stress and overeating is not…

The Teh finally hit the conservative pages of Scrip World Pharmaceutical News. Wyeth’s new antipsychotic receives FDA non-approvable letter after fatality August 13, 2007 Scrip The US FDA has issued a non-approvable letter for Wyeth/Solvay’s new-generation atypical antipsychotic bifeprunox, which was under review for the acute treatment of schizophrenia and the maintenance of stable adult…

Thumbs Down on Rimonabant

Following up on the wacky tobaccy post, the FDA advisory panel voted 14-0 against recommendation of rimonabant to move forward as a treatment for obesity, citing the need for further safety studies. As noted, the primary concerns are psychiatric/neurological issues. I really can’t resist a “No shit, Sherlock!” as pertains to the psychiatric and neurological…

Today, the FDA’s Endocrinologic and Metabologic Advisory Committee reviews rimonabant, the cannabinoid receptor antagonist developed by Sanofi-Aventis, for recommendations, or lack thereof, as an anti-obesity medication. Rimonabant was approved in Europe for limited cohorts of obese patients, but rejected as an anti-smoking medication. Approval for marketing rimonabant in the US is pending next month, and…